Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Josefina Galende"'
Autor:
Miguel Quijada-Álamo, María Hernández-Sánchez, Ana-Eugenia Rodríguez-Vicente, Claudia Pérez-Carretero, Alberto Rodríguez-Sánchez, Marta Martín-Izquierdo, Verónica Alonso-Pérez, Ignacio García-Tuñón, José María Bastida, María Jesús Vidal-Manceñido, Josefina Galende, Carlos Aguilar, José Antonio Queizán, Isabel González-Gascón y Marín, José-Ángel Hernández-Rivas, Rocío Benito, José Luis Ordóñez, Jesús-María Hernández-Rivas
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-11 (2021)
Abstract BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases harboring del(11q). In addition, truncating mutations in the remaining allele of this gene can lead to BIRC3 biallelic inactivation, which has been sho
Externí odkaz:
https://doaj.org/article/6298fa088832472aaa3af17d993dc8f6
Autor:
Miguel Quijada-Álamo, María Hernández-Sánchez, Cristina Robledo, Jesús-María Hernández-Sánchez, Rocío Benito, Adrián Montaño, Ana E. Rodríguez-Vicente, Dalia Quwaider, Ana-África Martín, María García-Álvarez, María Jesús Vidal-Manceñido, Gonzalo Ferrer-Garrido, María-Pilar Delgado-Beltrán, Josefina Galende, Juan-Nicolás Rodríguez, Guillermo Martín-Núñez, José-María Alonso, Alfonso García de Coca, José A. Queizán, Magdalena Sierra, Carlos Aguilar, Alexander Kohlmann, José-Ángel Hernández, Marcos González, Jesús-María Hernández-Rivas
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-11 (2017)
Abstract Background Chronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic alterations may appe
Externí odkaz:
https://doaj.org/article/4acf3a07c16a4b30b54b74c2ed17f62b
Autor:
José Ángel Hernández, María Hernández-Sánchez, Ana Eugenia Rodríguez-Vicente, Vera Grossmann, Rosa Collado, Cecilia Heras, Anna Puiggros, Ana África Martín, Noemí Puig, Rocío Benito, Cristina Robledo, Julio Delgado, Teresa González, José Antonio Queizán, Josefina Galende, Ignacio de la Fuente, Guillermo Martín-Núñez, José María Alonso, Pau Abrisqueta, Elisa Luño, Isabel Marugán, Isabel González-Gascón, Francesc Bosch, Alexander Kohlmann, Marcos González, Blanca Espinet, Jesús María Hernández-Rivas, Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC)
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143073 (2015)
To analyze the impact of the 11q deleted (11q-) cells in CLL patients on the time to first therapy (TFT) and overall survival (OS), 2,493 patients with CLL were studied. 242 patients (9.7%) had 11q-. Fluorescence in situ hybridization (FISH) studies
Externí odkaz:
https://doaj.org/article/6572f0a44cbe4c42af91d0ad5ea4aa40
Autor:
José Ángel Hernández, Ana Eugenia Rodríguez, Marcos González, Rocío Benito, Celia Fontanillo, Virgilio Sandoval, Mercedes Romero, Guillermo Martín-Núñez, Alfonso García de Coca, Rosa Fisac, Josefina Galende, Isabel Recio, Francisco Ortuño, Juan Luis García, Javier de las Rivas, Norma Carmen Gutiérrez, Jesús F. San Miguel, Jesús María Hernández
Publikováno v:
Haematologica, Vol 94, Iss 3 (2009)
Background Among patients with B-cell chronic lymphoid leukemia, those with 13q14 deletion have a favorable outcome. However, whether the percentage of cells with 13q- influences the prognosis or the biological characteristics of this disease is unkn
Externí odkaz:
https://doaj.org/article/c047355b29f14df8a2d302f814a0e0f6
Autor:
Claudia Pérez‐Carretero, María Hernández‐Sánchez, Teresa González, Miguel Quijada‐Álamo, Marta Martín‐Izquierdo, Sandra Santos‐Mínguez, Cristina Miguel‐García, María‐Jesús Vidal, Alfonso García‐De‐Coca, Josefina Galende, Emilia Pardal, Carlos Aguilar, Manuel Vargas‐Pabón, Julio Dávila, Isabel Gascón‐Y‐Marín, José‐Ángel Hernández‐Rivas, Rocío Benito, Jesús‐María Hernández‐Rivas, Ana‐Eugenia Rodríguez‐Vicente
Publikováno v:
American Journal of Hematology. 97:903-914
Interstitial 14q32 deletions involving IGH gene are infrequent events in chronic lymphocytic leukemia (CLL), affecting less than 5% of patients. To date, little is known about their clinical impact and molecular underpinnings, and its mutational land
Autor:
Erik de Cabo López, Ma. Jesús Vidal-Manceñido, Josefina Galende del Canto, Carmen Aguilera Sanz, Marta Megido Lahera, Alicia Smucler Simonovich, Sheila Bodelón Gago, Carlos A. Cuenca Aprell
Publikováno v:
Revista Sangre (ENG). 41
Autor:
Erik de Cabo López, Ma. Jesús Vidal-Manceñido, Josefina Galende del Canto, Carmen Aguilera Sanz, Marta Megido Lahera, Alicia Smucler Simonovich, Sheila Bodelón Gago, Carlos A. Cuenca Aprell
Publikováno v:
Revista Sangre. 41
Autor:
José María Bastida, María Jesús Vidal-Manceñido, Josefina Galende, Ana-Eugenia Rodríguez-Vicente, Jesús María Hernández-Rivas, Ignacio García-Tuñón, Marta Martín-Izquierdo, Jose Angel Hernandez-Rivas, Isabel González-Gascón y Marín, José Antonio Queizán, Alberto Rodríguez-Sánchez, Miguel Quijada-Álamo, José Luis Ordóñez, Verónica Alonso-Pérez, Carlos Aguilar, Rocío Benito, Claudia Pérez-Carretero, María Hernández-Sánchez
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-11 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-11 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
© The Author(s) 2021.
BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases harboring del(11q). In addition, truncating mutations in the remaining allele of this gene can lead to BIRC3 biallelic inactivation,
BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases harboring del(11q). In addition, truncating mutations in the remaining allele of this gene can lead to BIRC3 biallelic inactivation,
Autor:
Verónica Pérez, Claudia Pérez Carretero, Jesús María Hernández-Rivas, Maria Vidal, Ignacio García-Tuñón, José Luis Ordóñez, Josefina Galende Del Canto, Isabel González-Gascón y Marín, José Antonio Queizán, Ana E. Rodriguez, José María Bastida, Marta Martín Izquierdo, Miguel Quijada Álamo, María Hernández-Sánchez, José-Ángel Hernández, Rocío Benito, Carlos Aguilar
Publikováno v:
Blood. 136:4-4
Chronic lymphocytic leukemia (CLL) patients harboring 11q22.3 deletion, del(11q), are characterized by a rapid disease progression. One of the suggested genes to be involved in the pathogenesis of this deletion is BIRC3, a negative regulator of NF-κ
Autor:
Josefina Galende, Paloma Bárcena, Diego Alignani, Alfonso García de Coca, Maria-Luz Sanchez, Noemi Puig, Rebeca Cuello, Alberto Orfao, Maria-Victoria Mateos, Luis A. Corchete, María-Belén Vidriales, José L. Alonso, Abelardo Bárez, Bruno Paiva, Cristina Jimenez, Irene Aires-Mejia, Maria-Carmen Montes, Norma C. Gutiérrez, Ramón García-Sanz, Tomás José González-López, José Augusto Evangelho Hernandez, M. E. Sarasquete, Jesús F. San Miguel, Enrique M. Ocio, Fernando Escalante, Magdalena Sierra, José de Jesús Pérez, Emilia Pardal
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Although information about the molecular pathogenesis of Waldenström macroglobulinemia (WM) has significantly advanced, the precise cell of origin and the mechanisms behind WM transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undet